Good response to leucovorin and fluorouracil plus oxaliplatin and cetuximab therapy in a patient with metastatic ascending colon cancer harboring a KRAS p.G13D mutation

De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 304:1812–1820. 2010.PubMed/NCBI

Bando H, Yoshino T, Shinozaki E, et al: Clinical outcome in patients with metastatic colorectal cancer harboring KRAS p. G13D mutation treated with cetuximab. J Clin Oncol. 29:4482011.

Tejpar S, Bokemeyer C, Celik I, et al: Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 29:35112011.

Mayer A, Takimoto M, Fritz E, et al: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 71:2454–2460. 1993. View Article : Google Scholar : PubMed/NCBI

Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 21:2787–2799. 2003. View Article : Google Scholar : PubMed/NCBI

Van Cutsem E, Nowacki M, Lang I, et al: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol. 25:40002007.PubMed/NCBI

Yoshino T, Watanabe T, Yamazaki K, et al: Japan Study Group of KRAS Mutation in Colorectal Cancer: Clinicopathological features in metastatic colorectal cancer patients with KRAS wild type compared with codon 12 and codon 13 mutant: Results from a multicenter, cross-sectional study by the Japan study group of KRAS mutation in colorectal cancer. J Clin Oncol. 29:4072011.

Brink M, De Goeij AF, Weijenberg MP, et al: K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. 24:703–710. 2003. View Article : Google Scholar : PubMed/NCBI

Sarela AI, Guthrie JA, Seymour MT, et al: Non-operative management of the primary tumor in patients with incurable stage IV colorectal cancer. Br J Surg. 88:1352–1356. 2001. View Article : Google Scholar : PubMed/NCBI

Muratore A, Zorzi D, Bouzari H, et al: Asymptomatic colorectal cancer with un-resectable liver metastasis: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol. 14:766–770. 2006. View Article : Google Scholar

Mentha G, Majno PE, Andres A, et al: Neoadjuvant chemotherapy and resection of advanced synchronous liver metastasis before treatment of the colorectal primary. Br J Surg. 93:872–878. 2006. View Article : Google Scholar

Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumorKRAS and BRAF mutation status. J Clin Oncol. 33:50912010.PubMed/NCBI

Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. doi: 10.1093.annonc.mdq632. 2011. View Article : Google Scholar : PubMed/NCBI

Van Cutsem E, Lang I, D’Haens G, et al: KRAS status and efficacy in the Crystal study: 1st line treatment for patients with metastatic colorectal cancer receiving FOLFIRI with or without cetuximab. Ann Oncol. 19:7102008.